Guideline review

Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)

Paul N Brennan,1,2 Peter Cartlidge,3 Thomas Manship,4 John F Dillon,5

ABSTRACT

The European Association for the Study of the Liver has produced extensive guidelines for the investigation and management of drug-induced liver injury. Here, we provide a commentary and overview of some of the principle disease investigations and management that arise from these guideline recommendations.

OVERVIEW/COMMENTARY

Guidelines have been produced by the European Association for the Study of the Liver for the investigation and management of drug-induced liver injury (DILI). DILI is epitomised by a myriad of presentations and idiosyncrasies, posing significant diagnostic challenge to gastroenterologists and hepatologists.

DILI is traditionally classified as intrinsic (or direct) versus idiosyncratic. Characteristically, intrinsic DILI is usually predictable, dose-related phenomenon, occurring in a large subset of exposed individuals, with relatively short time to onset. Idiosyncratic DILI is not usually dose-related; however, a dose threshold is generally required, with variable latency of onset; from days to weeks.1

In addition to specific drug-related properties, there are important host predisposing factors including advancing age, sex, alcohol intake and underlying liver disease. Female sex appears to confer a higher risk of risk for DILI and have a higher risk of progression to acute liver failure.1 There are additional genetic drivers for DILI which vary widely and are covered extensively in the original guidelines.

A general approach to a suspected case of DILI is presented in figure 1. This includes taking a comprehensive medical and drug history, with clear timing around drug usage. Potential agents may include both prescribed and non-prescribed compounds, herbal and dietary supplements (HDS), over-the-counter products and illicit substances.

HDS-associated liver toxicity appears to be an emerging determinant of DILI, with wide geographical variability. A prospective study in Iceland purported 16% of DILI related to HDS,2 while the US Drug-Induced Liver Injury Network reported a similar percentage (16%), with an increase from 7% from 2004 to 2005 to 20% in 2013–2014.3 Further case–control data suggested rates of 4%–5% in studies in Latin America4 and Germany,5 respectively.

DILI should be classified according to the dominant pattern of liver enzyme derangement; hepatocellular, cholestatic and mixed injury (figure 1).
Initially, alanine transferase (ALT) activity (patients ALT/upper limit of normal (ULN) of ALT) and alkaline phosphatase (ALP) activity (patients ALP/ULN of ALP) is calculated. Then ALT/ALP ratio (R) is determined. Some of the other commonly encountered phenotypes, and characteristic findings and commonly implicated agents are summarised in table 1.

ALT, ALP and bilirubin are the typical indices used to define liver damage, and liver dysfunction in DILI and serial measurements are necessary to portray extent of hepatocellular injury and DILI phase. ALT is sensitive for hepatocyte injury, particularly alongside an elevated bilirubin and this pattern is a reliable biomarker of liver injury in DILI. Elevated aminotransferases do not reflect the extent to which the liver is damaged, particularly in insidious variants of hepatotoxicity such as indolent fibrosis, vascular liver disorders, cirrhosis and microvesicular steatosis secondary to mitochondrial toxicity. Elevated ALP values usually indicate cholestatic damage, which combined with elevated GGT provides evidence the ALP elevation is of hepatic origin. Isolated hyperbilirubinaemia does not qualify as DILI, given possibility of multiple confounding diagnoses. One important consideration...
is mild transaminase rises that may be apparent in relation to statin therapy, this may simply reflect an adaptive response and does not represent a true DILI. As such, given the benefit of statins in NAFLD (Non-alcoholic fatty liver disease; NAFD), such therapies should be continued where feasible.

Patients with DILI should undergo testing for hepatotropic viruses including hepatitis (A–E), particularly in those with acute hepatocellular injury. For completeness an autoantibody screen (antinuclear antibody, anti-smooth muscle antibody (ASMA)), M2-anti-mitochondrial antibody (AMA), liver microsomal antibody, immunoglobulins) should be undertaken. DILI assessment should also include coagulation profiles, as elevated prothrombin time ratio values may suggest impending acute liver failure (ALF) and prompt referral to a liver transplant unit should be considered.

Abdominal ultrasound should be undertaken in all patients suspected of DILI to exclude any biliary, parenchymal or vasculopathy, additional imaging is dependent on the clinical context.

Liver biopsy may be reasonable to consider in DILI, as histology may provide information pertaining to severity of liver injury and provide mechanistic insights by identifying specific patterns of injury. Liver biopsy is also warranted in those patients suspected of DILI when serology raises the possibility of autoimmune hepatitis. Liver biopsy may also be considered in patients whereby suspected DILI progresses, or fails to resolve on withdrawal of the causal agent, since histology may provide prognostic information assisting clinical decision particularly regarding immunosuppression. There are characteristic histological patterns associated with individual check-point inhibitors including presence of ring granulomas and endotheliitis which may aid decision making around immunosuppression. In select cases of DILI, human leucocyte antigen genotyping can be used, whereby genetic determination may aid diagnosis and management, particularly those with features compatible with autoimmune hepatitis.

Given the non-specific nature of traditionally employed liver enzyme measurements there is increasing interest in determining novel serum biomarkers. These markers include glutamate dehydrogenase, keratin 18, glutathione S-transferase, sorbitol dehydrogenase, bile acids, cytochrome P450 and osteopontin. These markers may help to improve the specificity of DILI diagnosis, and aid prognostication. Presently, however, none are routinely employed, but represent exciting future avenues of research.

Rechallenging patients who had initial drug-related liver injury can lead to rapid, progressive liver insult often worse than previous with fulminant hepatic failure. A positive rechallenge is defined as an ALT > 3 ULN and is the strongest proof of drug causality. Some essential, irreplaceable medications may be used to rechallenge patients including; antituberculous and chemotherapy agents, however, this should only be considered with meticulous monitoring arrangements under specialist supervision.

### Table 1 Classification of DILI based on liver enzyme derangement

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Case definition</th>
<th>Commonly implicated agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Idiosyncratic</td>
<td>Hepatocellular: If ALT alone is elevated less than fivefold above ULN or R5.</td>
<td>Antimicrobials, anticonvulsants, antiarrhythmic, androgens, oestrogens/progesterone, immunomodulatory and antineoplastic</td>
</tr>
<tr>
<td></td>
<td>Cholestatic: ALP alone is elevated less than twofold above ULN or R2.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mixed: R2 &gt; 2 to &lt; 5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic DILI: DILI with acute presentation, with evidence of persistent liver injury at &gt; 1 year after its onset</td>
<td></td>
</tr>
<tr>
<td>Drug reaction with eosinophilia and systemic symptoms</td>
<td>Drug-related hypersensitivity with eosinophilia and systemic inflammation</td>
<td>Anticonvulsants, NRTIs</td>
</tr>
<tr>
<td>Drug-induced autoimmune hepatitis</td>
<td>Acute DILI with serological and/or histological features of AIH</td>
<td>NSAIDs, statins, minocycline and nitrofurantoin</td>
</tr>
<tr>
<td>Secondary sclerosing cholangitis</td>
<td>Presenting as acute DILI with histological/radiological features of sclerosing cholangiopathy</td>
<td>Inhalational anaesthetics, atorvastatin, 6-MP</td>
</tr>
<tr>
<td>Granulomatous hepatitis</td>
<td>Granulomas on histology with exposure to implicated agent(s)</td>
<td>Anticonvulsants, sulphonamides</td>
</tr>
<tr>
<td>Acute fatty liver</td>
<td>Acute development of microvesicular steatohepatitis</td>
<td>Reverse transcriptase inhibitors</td>
</tr>
<tr>
<td>Drug-associated fatty liver disease</td>
<td>Consistent with NAFLD and attributable exposure</td>
<td>Methotrexate, corticosteroids, 5-FU</td>
</tr>
<tr>
<td>Nodular regenerative hyperplasia</td>
<td>Diffuse nodularity organised around central hepatocytes</td>
<td>Antineoplastic/cytotoxic</td>
</tr>
<tr>
<td>Ductopaenia</td>
<td>Chronic cholestasis and ductular loss</td>
<td>Antimicrobials (β-lactams, tetracyclines and sulphonamides)</td>
</tr>
<tr>
<td>Liver tumours</td>
<td>Features of hepatocellular adenoma or carcinoma</td>
<td>Anabolic androgenic steroids and oral contraceptives</td>
</tr>
</tbody>
</table>

5-FU, 5-fluorouracil; 6-MP, 6-mercaptopurine; AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine transferase; DILI, drug-induced liver injury; NAFLD, non-alcoholic fatty liver disease; NRTI, nucleoside reverse transcriptase inhibitor; NSAID, non-steroidal antiinflammatory drug; ULN, upper limit of normal.
Another novel causative potentiator of DILI is those related to the classes of novel immunomodulatory therapeutic classes. These molecules are being increasingly used to treat malignancy through restitution of strong humoral, antitumour immune response, thereby improving patient survival. The reduction in tumour tolerance induced by immune checkpoint inhibitors can lead to inflammatory side effects, and an increase in immune related adverse events, including hepatotoxicity. Risk factors include the type of check point inhibitor, higher dose, autoimmune predisposition, pre-existing liver disease and the use of combination agents.9 10 Hepatotoxicity is heterogeneous ranging from mild transaminase derangement to pronounced acute hepatitis and fulminant liver failure. Assessment of severity can be determined using Common Terminology Criteria for Adverse Events scale and persistent grade 2–4 hepatotoxicity, then immunosuppression should be considered, along with cessation of the causative agent. The American Gastroenterological Association (AGA) has produced a practice update relating to this including outline of treatment strategies including corticosteroids and steroid-sparing agents.11

The Council for International Organisations of Medical Sciences scale can be used to assess DILI causality and consists of seven domains. The score categorises cases as highly probable (>8), probable (6–8), possible (3–5), unlikely (1–2) or excluded (<0) and is useful in initially evaluating likelihood of suspected DILI.

The principle management of suspected DILI is discontinuation of the likely causative agent. In the majority of DILI, spontaneous recovery occurs, without any need for treatment or specific supportive measures. This aspect of spontaneous recovery following discontinuation of an offending substance forms an important criterion in the causality assessment of DILI. There is no strong evidence for use of N-acetyl cysteine) except in paracetamol and ALF. Of note, there is no role for corticosteroids beyond cases of presumed autoimmune hepatitis and immune-related adverse reactions or for the use of ursodeoxycholic acid in cholestatic DILI.

DILI remains a challenging presentation with specific diagnostic and treatment complexities. Notwithstanding this, there remain a number of outstanding aspects of disease pathogenesis and predisposing factors that necessitate further exploration. There also exists, a clear need for novel biomarkers and predictors of outcome, beyond existing genetic determinants. The advent of novel treatment modalities, particularly oncological immune modifiers pose another challenging paradigm, and clinicians should be aware of their potential for hepatotoxicity.

One particularly useful resource which clinicians should be aware of is LiverTox.12 LiverTox provides contemporaneous, unbiased, and accessible reports on the diagnosis, cause, frequency, clinical patterns and management of liver injury attributable to prescription, non-prescription medications and selected HDS products.

Overall, however, given the inherent complexity of DILI, we would encourage clinicians to refer to the original guideline for points of reference as a definitive overview on the subject matter.

Twitter Paul N Brennan @brennap9
Contributors PNB reviewed the guideline and drafted initial manuscript. PC and TM reviewed the literature and prepared relevant sections and reviewed final document. JFD revised the manuscript critically for important intellectual content and provided critical appraisal.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or non-for-profit sectors.

Competing interests JFD has received research grants and lecture honoraria from MSD, Abbvie and Gilead.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

DILI remains a challenging presentation with specific diagnostic and treatment complexities. Notwithstanding this, there remain a number of outstanding aspects of disease pathogenesis and predisposing factors that necessitate further exploration. There also exists, a clear need for novel biomarkers and predictors of outcome, beyond existing genetic determinants. The advent of novel treatment modalities, particularly oncological immune modifiers pose another challenging paradigm, and clinicians should be aware of their potential for hepatotoxicity.

One particularly useful resource which clinicians should be aware of is LiverTox.12 LiverTox provides contemporaneous, unbiased, and accessible reports on the diagnosis, cause, frequency, clinical patterns and management of liver injury attributable to prescription, non-prescription medications and selected HDS products.

Overall, however, given the inherent complexity of DILI, we would encourage clinicians to refer to the original guideline for points of reference as a definitive overview on the subject matter.

Twitter Paul N Brennan @brennap9
Contributors PNB reviewed the guideline and drafted initial manuscript. PC and TM reviewed the literature and prepared relevant sections and reviewed final document. JFD revised the manuscript critically for important intellectual content and provided critical appraisal.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or non-for-profit sectors.

Competing interests JFD has received research grants and lecture honoraria from MSD, Abbvie and Gilead.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Paul N Brennan http://orcid.org/0000-0001-8368-1478
John F Dillon http://orcid.org/0000-0002-2164-4476

REFERENCES

